At this point, it’s no secret that SpaceX CEO Elon Musk wants humanity to become a multi-planet species, with the first target for colonization being Mars. Naturally, one of the biggest questions in such an endeavor is the cost of actually getting there. In a recently published article, it would seem that Musk intends to limit the price of a space ticket at $200,000.
The article is actually a transcript of the speech that Musk gave during the International Astronautical Congress, which was held in Mexico the previous year. Published in New Space, it basically talks about how humanity can become a multi-planet species, why this needs to happen, and what it would take to make it happen.
As the article indicates, the SpaceX boss recognizes that charging passengers $10 billion for a ticket to Mars would be an unrealistic way to create a self-sustaining society on the Red Planet. As such, the ideal range would be a few hundred thousand dollars, which is equivalent to the costs of an average house in the US.
Despite the admittedly exorbitant price, it’s worth noting that much of that money is actually going to resources and preparations that will actually get humans to Mars safely. More to the point, $200,000 is already incredibly cheap when factoring in how much an average rocket launch would cost with humans onboard.
In any case, Musk also outlined how he is going to get the ticket prices to such a cheap figure and it starts with making spaceships reusable. SpaceX is already well on its way to achieving this milestone thanks to its recent missions involving a used Falcon 9 rocket and Dragon cargo ship, Futurism reports.
There’s also the matter of the type of fuel that these ships will use since those will add to the weight of the ship and the costs. Musk suggests making use of methane due to its abundance on Mars.


Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Neuralink Expands Brain Implant Trials with 12 Global Patients
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment




